PMID- 26001206
OWN - NLM
STAT- MEDLINE
DCOM- 20170503
LR  - 20181202
IS  - 1563-5279 (Electronic)
IS  - 0020-7454 (Linking)
VI  - 126
IP  - 4
DP  - 2016
TI  - The peroxisome proliferators activated receptor-gamma agonists as therapeutics 
      for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's 
      disease: a meta-analysis.
PG  - 299-307
LID - 10.3109/00207454.2015.1015722 [doi]
AB  - Alzheimer's disease (AD) is a devastating neurodegenerative disease and there is 
      no effective therapy for it. Peroxisome proliferators activated receptor-gamma 
      (PPAR-gamma) agonists is a promising therapeutic approach for AD and has been widely 
      studied recently, but no consensus was available up to now. To clarify this 
      point, a meta-analysis was performed. We searched MEDLINE, EMBASE, Cochrane 
      Central database, PUBMED, Springer Link database, SDOS database, CBM, CNKI and 
      Wan fang database by December 2014. Standardized mean difference (SMD), relative 
      risk (RR) and 95% confidence interval (CI) were calculated to assess the strength 
      of the novel therapeutics for AD and mild-to-moderate AD. A total of nine studies 
      comprising 1314 patients and 1311 controls were included in the final 
      meta-analysis. We found the effect of PPAR-gamma agonists on Alzheimer's Disease 
      Assessment Scale - Cognitive Subscale (ADAS-cog) scores by using STATA software. 
      There was no evidence for obvious publication bias in the overall meta-analysis. 
      There is insufficient evidence of statistically incognition of AD and 
      mild-to-moderate AD patients have been improved who were treated with PPAR-gamma 
      agonists in our research. However, PPAR-gamma agonists may be a promising therapeutic 
      approach in future, especially pioglitazone, with large-scale randomized 
      controlled trials to confirm.
FAU - Cheng, Huawei
AU  - Cheng H
AD  - a Department of Pharmacy, Anhui Cancer Hospital , Hefei , China.
FAU - Shang, Yuping
AU  - Shang Y
AD  - a Department of Pharmacy, Anhui Cancer Hospital , Hefei , China.
FAU - Jiang, Ling
AU  - Jiang L
AD  - b Department of Pharmacy, Anhui Provincial Hospital , Hefei , China.
FAU - Shi, Tian-lu
AU  - Shi TL
AD  - b Department of Pharmacy, Anhui Provincial Hospital , Hefei , China.
FAU - Wang, Lin
AU  - Wang L
AD  - c Clinical Laboratory, the First Affiliated Hospital of Anhui University of 
      Chinese Medicine , Hefei , China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20150522
PL  - England
TA  - Int J Neurosci
JT  - The International journal of neuroscience
JID - 0270707
RN  - 0 (Benzimidazoles)
RN  - 0 (Benzoates)
RN  - 0 (PPAR gamma)
RN  - 0 (Thiazolidinediones)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - U5SYW473RQ (Telmisartan)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Alzheimer Disease/*drug therapy/*metabolism
MH  - Benzimidazoles/*therapeutic use
MH  - Benzoates/*therapeutic use
MH  - Humans
MH  - PPAR gamma/*agonists
MH  - Pioglitazone
MH  - Rosiglitazone
MH  - Telmisartan
MH  - Thiazolidinediones/*therapeutic use
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - PPAR-gamma agonists
OT  - meta-analysis
EDAT- 2015/05/23 06:00
MHDA- 2017/05/04 06:00
CRDT- 2015/05/23 06:00
PHST- 2015/05/23 06:00 [entrez]
PHST- 2015/05/23 06:00 [pubmed]
PHST- 2017/05/04 06:00 [medline]
AID - 10.3109/00207454.2015.1015722 [doi]
PST - ppublish
SO  - Int J Neurosci. 2016;126(4):299-307. doi: 10.3109/00207454.2015.1015722. Epub 
      2015 May 22.